Abstract Number: 0187 • ACR Convergence 2022
Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
Background/Purpose: COMPACT is a non-interventional study evaluating the persistence, effectiveness, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA), axial-spondyloarthritis or psoriatic arthritis…Abstract Number: 0809 • ACR Convergence 2021
The Impact of Flares on Clinical and Patient Reported Outcomes in Rheumatoid and Undifferentiated Arthritis Patients
Background/Purpose: There are many definitions of flare in rheumatoid arthritis (RA). Loss of low disease activity is associated with clinically relevant deterioration. Patients in DAS…Abstract Number: 0818 • ACR Convergence 2021
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…Abstract Number: 1266 • ACR Convergence 2021
Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus
Background/Purpose: Childhood systemic lupus erythematosus (cSLE) is a life-long disease with significant morbidity and mortality, and with associated significant impact on health-related quality of life…Abstract Number: 1777 • ACR Convergence 2021
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) experience chronic pain due to inflammatory attributes of their disease. Nonsteroidal anti‑inflammatory drugs and biologics…Abstract Number: 0153 • ACR Convergence 2020
Counseling on Safe Driving Strategies in Patients with Osteoarthritis and Rheumatoid Arthritis
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis (RA) cause functional impairments that impact daily life activities, including automobile driving. Radiographic presence of OA on knee and…Abstract Number: 0329 • ACR Convergence 2020
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ-DI) has been validated and widely used in psoriatic arthritis (PsA) clinical trials for the assessment of patient…Abstract Number: 0536 • ACR Convergence 2020
Systematic Geriatric Assessment in Older Patients with Rheumatic Diseases – The RheuMAGIC Pilot Study
Background/Purpose: Current demographic data predict that the number of older adults with rheumatic diseases will considerably increase in the coming years. Geriatric patients differ from…Abstract Number: 0758 • ACR Convergence 2020
Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity…Abstract Number: 1335 • ACR Convergence 2020
Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Background/Purpose: To describe the demographic and clinical characteristics of patients with inflammatory arthritis (IA) initiating biologic disease modifying anti-rheumatic drugs (bDMARD) who use complementary and…Abstract Number: 1363 • ACR Convergence 2020
Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
Background/Purpose: The phase 3 randomized controlled trial FUTURE 5 (NCT02404350) showed the efficacy of secukinumab (SEC) improving clinical signs, symptoms, and radiographic progression in patients…Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…Abstract Number: 1736 • ACR Convergence 2020
Health Assessment Questionnaire Predicts All-Cause Mortality at One Year in Patients with Early Rheumatoid Arthritis
Background/Purpose: Patients with RA are at greater risk of mortality than the general population. Higher HAQ disability has been associated with hospitalizations and mortality in…Abstract Number: 1880 • ACR Convergence 2020
Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability…Abstract Number: 1891 • ACR Convergence 2020
Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…